SBIR Phase I: AK-423: A broad-spectrum antiviral and immunomodulatory agent (COVID-19)

SBIR 第一期：AK-423：一种广谱抗病毒和免疫调节剂 (COVID-19)

• 批准号: 2032097
• 负责人: Sherine Abdelmawla
• 金额: $ 25.6万
• 依托单位: Akanocure Pharmaceuticals, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2032097&HistoricalAwards=false
• 关键词: SBIR; Phase; AK; 423; broad

The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project stems from the development of an efficient broad-spectrum antiviral agent addressing the current COVID-19 pandemic. The approach can also address future outbreaks of other viruses. The project is targeting the group of COVID-19 patients who will develop severe illness featuring multiple organ dysfunction. Those patients need ICU units and ventilators in amounts that can overwhelm the health care system. This project will develop an antiviral agent to mitigate the social distancing measures and improve quality of life. This Small Business Innovation Research (SBIR) Phase I project focuses on the development AK-423, a potential efficient antiviral and immunomodulatory agent against COVID-19. The technical objectives focus on testing AK-423 (in-vitro and in-vivo) against COVID-19. Recent reports suggest that the multi-organ damage that occurs during COVID-19 infection is characterized by an exaggerated inflammatory response indicative of cytokine storm, auto-immunity, and a sepsis syndrome caused by complex abnormal immune reactions. An ideal treatment would not only suppress viral replication but would also regulate the abnormal immune response. AK-423 targets a host metabolic process that the virus hijacks. It is also a key process in the differentiation of lymphocytes. Inhibition of such process is proven to dampen the immune response, minimize immune response-induced tissue damage, inhibit production of pro-inflammatory cytokines, and efficiently shut down viral replication. This strategy will deliver an efficient broad-spectrum antiviral agent.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业创新研究 (SBIR) 第一阶段项目的更广泛影响/商业潜力源于针对当前 COVID-19 大流行的高效广谱抗病毒药物的开发。该方法还可以解决其他病毒未来的爆发。该项目针对的是患有多器官功能障碍的严重疾病的 COVID-19 患者群体。 这些患者需要的 ICU 病房和呼吸机的数量可能会让医疗保健系统不堪重负。该项目将开发一种抗病毒药物，以减轻社交距离措施并提高生活质量。该小企业创新研究 (SBIR) 第一阶段项目重点开发 AK-423，这是一种针对 COVID-19 的潜在高效抗病毒和免疫调节剂。技术目标侧重于针对 COVID-19 测试 AK-423（体外和体内）。最近的报告表明，COVID-19 感染期间发生的多器官损伤的特点是夸大的炎症反应，表明细胞因子风暴、自身免疫以及复杂的异常免疫反应引起的败血症综合征。理想的治疗不仅能抑制病毒复制，还能调节异常的免疫反应。 AK-423 针对病毒劫持的宿主代谢过程。这也是淋巴细胞分化的关键过程。事实证明，抑制这一过程可以抑制免疫反应，最大限度地减少免疫反应引起的组织损伤，抑制促炎细胞因子的产生，并有效地阻止病毒复制。该策略将提供一种高效的广谱抗病毒药物。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响审查标准进行评估，被认为值得支持。